Eli Lilly & Co. is intensifying its efforts to combat the illicit market for retatrutide, an experimental weight-loss drug. The company has filed lawsuits against businesses in the US, particularly in Texas, that are illegally selling the drug. Lilly is also urging regulators to take stronger action against this growing public health crisis, which involves unregulated foreign manufacturers and misleading online advertisements. This issue is particularly concerning as retatrutide is not yet approved by any global regulatory bodies, and the company fears that safety issues with counterfeit versions could damage the drug's reputation. AI
RANK_REASON Company action against counterfeit products, not a new release or core research.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
